Hepatitis C Therapy - Maxygen Announces Achievement of Milestone in Roche Alliance

Maxygen Announces Achievement of Milestone in Roche Alliance
FinanzNachrichten - Dec 14 4:48 AM
REDWOOD CITY, Calif., Dec. 14 /PRNewswire-FirstCall/ -- Maxygen, ( Nachrichten ) Inc. announced today that it has earned a $5 million milestone in its collaboration with Roche ( Nachrichten / Aktienkurs ) to develop improved interferon alpha protein therapeutics to treat hepatitis C virus (HCV) and hepatitis B virus (HBV) infections.Save to My Web

Gen-Probe to Webcast Presentation at the 24th Annual JPMorgan Healthcare Conference
RedNova - Jan 04 4:21 PM
SAN DIEGO, Jan. 4 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated announced today that the Company will present at the 24th Annual JPMorgan Healthcare Conference in San Francisco on January 10, 2006 at 10:30 a.m. Pacific Time (1:30 p.m. Eastern Time).Save to My Web

Mothers pass hepatitis C more often to infant girls
Reuters via Yahoo! News - Dec 15 12:27 PM
The results of a large European study suggest that mother-to-child transmission of hepatitis C virus (HCV) occurs significantly more often among girls than among boys.Save to My Web

InterMune Announces Divestiture of Oritavancin
RedNova - Dec 27 8:19 AM
BRISBANE, Calif., Dec. 27 /PRNewswire-FirstCall/ -- InterMune, Inc.Save to My Web

Partial 24-Week Data Demonstrate Valopicitabine (NM283) Combined with Pegylated Interferon Continues to Produce Greater
[Press Release] PR Newswire via Yahoo! Finance - Dec 14 6:56 AM
Idenix Pharmaceuticals, Inc. announced partial 24-week data today from an ongoing phase IIb clinical trial evaluating valopicitabine combined with pegylated interferon in treatment-refractory patients with chronic hepatitis C.Save to My Web